Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsMore about Open Access at the Crick
Authors listDennis Plenker Maximilian Riedel Johannes Brägelmann Marcel A Dammert Rakhee Chauhan Phillip P Knowles Carina Lorenz Marina Keul Mike Bührmann Oliver Pagel Verena Tischler Andreas H Scheel Daniel Schütte Yanrui Song Justina Stark Florian Mrugalla Yannic Alber André Richters Julian Engel Frauke Leenders Johannes M Heuckmann Jürgen Wolf Joachim Diebold Georg Pall Martin Peifer Maarten Aerts Kris Gevaert René P Zahedi Reinhard Buettner Kevan M Shokat Neil McDonald Stefan M Kast Oliver Gautschi Roman K Thomas Martin L Sos
Toggle all authors (35)
Oncogenic fusion events have been identified in a broad range of tumors. Among them, rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. We provide further evidence that current anti-RET drugs may not be potent enough to induce durable responses in such tumors. We report that potent inhibitors, such as AD80 or ponatinib, that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill -rearranged tumors. Using chemical genomics in conjunction with phosphoproteomic analyses in -rearranged cells, we identify the CCDC6-RET mutation and drug-induced mitogen-activated protein kinase pathway reactivation as possible mechanisms by which tumors may escape the activity of RET inhibitors. Our data provide mechanistic insight into the druggability of RET kinase fusions that may be of help for the development of effective therapies targeting such tumors.
Journal Science Translational Medicine
Issue number 394